Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo
Summary: EG.5.1 is a subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB variant that is rapidly increasing in prevalence worldwide. However, the pathogenicity, transmissibility, and immune evasion properties of isolates of EG.5.1 are largely unknown. Here, we...
Main Authors: | Ryuta Uraki, Maki Kiso, Kiyoko Iwatsuki-Horimoto, Seiya Yamayoshi, Mutsumi Ito, Shiho Chiba, Yuko Sakai-Tagawa, Masaki Imai, Yukie Kashima, Michiko Koga, Noriko Fuwa, Nobumasa Okumura, Masayuki Hojo, Noriko Iwamoto, Hideaki Kato, Hideaki Nakajima, Norio Ohmagari, Hiroshi Yotsuyanagi, Yutaka Suzuki, Yoshihiro Kawaoka |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Cell Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124723015929 |
Similar Items
-
Transmission and re-infection of Omicron variant XBB.1.5 in hamstersResearch in context
by: Peter J. Halfmann, et al.
Published: (2023-07-01) -
An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
by: Ryuta Uraki, et al.
Published: (2024-01-01) -
Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
by: Ryuta Uraki, et al.
Published: (2023-05-01) -
Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
by: Aya Ishizaka, et al.
Published: (2023-07-01) -
Gut dysbiosis promotes the breakdown of oral tolerance mediated through dysfunction of mucosal dendritic cells
by: Tomohiro Fukaya, et al.
Published: (2023-05-01)